Antibodies News and Research

RSS

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.

1 Mar 2011

AFFiRiS announces significant progress in collaboration with GSK for Alzheimer's vaccine development

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals for the development of an active vaccination programme against Alzheimer's disease.

1 Mar 2011

AFFiRiS AG - Alzheimer's vaccines generate further cash flow

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals (GSK) for the development of an active vaccination programme against Alzheimer´s disease. While the lead vaccine candidate AD02 is currently in phase II clinical testing, two additional preclinical programmes have been completed successfully. The second programme was related to alternative vaccine candidates generated by AFFiRiS´ AFFITOME® technology, including candidate AD03. Based on the promising preliminary results of this programme, GSK exercised its option for the alternative vaccine candidates which triggered a EUR 2.5 million payment to AFFiRiS. An additional EUR 1 million payment became due simultaneously for the successful completion of tests of alternative vaccine formulations.

28 Feb 2011

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

biOasis Technologies Inc. is pleased to announce the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its Cognitest™ blood test for Alzheimer's disease.

28 Feb 2011

Arsanis closes Series A financing for $10 million

Arsanis, Inc, a recently founded biotechnology company dedicated to the development of anti-infective monoclonal antibody therapeutics, today announced the closing of a Series A financing with a total funding amount of $10 million. Proceeds from the initial financing will be used to advance several programs in the anti-microbial infectious disease area.

28 Feb 2011

FUJIFILM enters definitive agreement to acquire Merck

FUJIFILM Corporation and Merck, known as MSD outside the United States and Canada, today announced they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceutical industry and wholly owned by Merck.

28 Feb 2011

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found.

25 Feb 2011

New vaccine offers hope against Hepatitis C

Immunology: Three percent of the world's population is currently infected by hepatitis C. The virus hides in the liver and can cause cirrhosis and liver cancer, and it's the most frequent cause of liver transplants in Denmark.

24 Feb 2011

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Cell Signaling Technology, Inc. of Danvers, MA announced today a joint commercialization partnership with Astellas Pharma, Inc. of Tokyo, Japan focused on the delivery of personalized cancer therapeutics and diagnostics.

From Cell Signaling Technology 24 Feb 2011

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.

23 Feb 2011

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.

23 Feb 2011

New nanoparticle can help develop vaccines against HIV, malaria

MIT engineers have designed a new type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.

23 Feb 2011

FDA approves OraSure's rapid antibody test to detect HCV

OraSure Technologies, Inc. announced today that its OraQuick HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies with a fingerstick whole blood sample.

22 Feb 2011

NYBC urges African American, Hispanic descent to donate blood for special patients

A hospitalized single mother from Queens is calling for more African Americans to become blood donors, so that she and many others may be able to live. People may call New York Blood Center at 1-800-933-BLOOD or visit www.nybloodcenter.org for more information about giving blood, and where to donate.

22 Feb 2011

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.

21 Feb 2011

U.S. FDA approves Corifact to prevent bleeding in people with Factor XIII deficiency

The U.S. Food and Drug Administration today approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.

18 Feb 2011

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Progenics Pharmaceuticals, Inc. today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen.

17 Feb 2011

Researchers develop new pneumococcal vaccine through novel discovery approach

Pneumococcus accounts for as much as 11 percent of mortality in young children worldwide. While successful vaccines like Prevnar exist, they are expensive and only work against specific pneumococcal strains, with the risk of becoming less effective as new strains emerge.

17 Feb 2011

New fully human monoclonal antibodies to battle Chikungunya

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS, a French biopharmaceutical company, announced today the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

16 Feb 2011

The Children's Hospital of Philadelphia establishes Jeffrey Modell Endowed Chair in Pediatric Immunology Research

The Children's Hospital of Philadelphia today announced the establishment of the Jeffrey Modell Endowed Chair in Pediatric Immunology Research.

16 Feb 2011

Antibodies News and Research

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

AFFiRiS announces significant progress in collaboration with GSK for Alzheimer's vaccine development

AFFiRiS AG - Alzheimer's vaccines generate further cash flow

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

Arsanis closes Series A financing for $10 million

FUJIFILM enters definitive agreement to acquire Merck

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

New vaccine offers hope against Hepatitis C

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

New nanoparticle can help develop vaccines against HIV, malaria

FDA approves OraSure's rapid antibody test to detect HCV

NYBC urges African American, Hispanic descent to donate blood for special patients

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

U.S. FDA approves Corifact to prevent bleeding in people with Factor XIII deficiency

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Researchers develop new pneumococcal vaccine through novel discovery approach

New fully human monoclonal antibodies to battle Chikungunya

The Children's Hospital of Philadelphia establishes Jeffrey Modell Endowed Chair in Pediatric Immunology Research

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo